National Lung Cancer Partnership 2008 Career Development Award Request for Applications
National Lung Cancer Partnership
All Regions
09/02/2008
$100,000

National Lung Cancer Partnership
2008 Career Development Award
Request for Applications

Purpose of Award
The award provides funding for clinical and basic science fellows and junior faculty to advance their careers in lung cancer etiology, prevention, early detection, treatment, and symptom management.

The Career Development Award is intended to provide "protected time" for fellows and newly independent investigators to develop their careers in lung cancer research. Applications will be judged on the quality of the applicant’s research, feasibility of the Career Development Plan, and the resources and environment available to the applicant, including the ability of the primary mentor to provide appropriate guidance and protected time during the award period. The applicant should state in the application how this award would advance their career.

The award will be provided for up to $50,000 per year ($100,000 maximum over 2 years). The award is designed to be used primarily for salary support, but can also be used for the support of research, including technical assistance, supplies or reagents. The award cannot be used to purchase major equipment for general use. It is the policy of National Lung Cancer Partnership not to provide indirect costs to the award recipient’s institution.

Eligibility
1. At the time of application, an applicant must hold a doctoral degree (MD, PhD, DO, DrPH, or equivalent), and be a post-doctoral fellow or be in the first 5 years of a faculty appointment at a not-for-profit institution. Pre-doctoral fellows are not eligible for the Career Development Award.
2. Applications will only be accepted from individuals involved in lung cancer research.
3. Applications will be accepted from individuals at US and Canadian sponsoring institutions. The applicant need not be a citizen of either country. If the applicant is not a US or Canadian citizen, verification of work visa must be provided.
4. There must be a Primary Mentor at the applicant’s institution who will oversee the applicant’s Career Development Plan. The Primary Mentor may only support one applicant.
5. The Career Development Award recipient must spend a minimum of 50 percent of her/his time in lung cancer research. This time should be free from major patient care, teaching, administrative, or other responsibilities.
6. The Career Development Award recipient may not hold another fellowship or award designed for career development at the time the Award is granted. The Award recipient is encouraged to hold other grants to support research costs.
7. The Career Development Award recipient may not have knowingly received any research funding from the tobacco industry, its parent companies, or subsidiaries, within the last 5 years.
8. Applications involving animals must receive approval from the institution’s Animal Care and Use Committee before award commencement.
9. Applications involving human participants must receive approval from the local Institutional Review Board before award commencement.
10. National Lung Cancer Partnership will not discriminate on the basis of gender, race, creed, religion, sexual orientation, disability, nationality, age or any other factor irrelevant to the quality of the application.

Award Information
The deadline for grant applications is September 2, 2008. Applications must be electronically submitted and postmarked on or before this deadline. Awards will be announced on or before December 15, 2008.

The Career Development Award is subject to annual review, and may be granted for a maximum of $50,000 per year for two years. The second year of support is based on the applicant’s demonstration of satisfactory progress.

Contact Us

National Lung Cancer Partnership
222 N. Midvale Blvd., Suite 6
Madison, WI 53705

Phone: 608.233.7905
Fax: 608.233.7893

E-mail: info@NationalLungCancerPartnership.org
www.NationalLungCancerPartnership.org

Physician Researcher, Junior Faculty, Junior Investigator, Junior Researcher, Junior Scientist, Oncologist, Young Investigator, Young Scientist
2009 AASLD/ALF Liver Scholar Award
American Association for the Study of Liver Diseases
All Regions
10/16/2008
$225,000

2009 AASLD/ALF Liver Scholar Award

Application Deadline: October 16, 2008
Recipient Notification: March 2009
Award Period: July 1, 2009 - June 30, 2012

Appplication coming soon!

The AASLD/ALF Liver Scholar Award is a three-year, basic science award of $75,000 per year that endeavors to encourage young investigators to pursue a career in liver-related research.

Overview
The goal of the Liver Scholar Award is to provide young scientists with support for their research to bridge the gap between completion of research training and attainment of status as an independent research scientist. The additional research experience provided by this award is intended to enable them to successfully compete for research grants from national sources, particularly the NIH. The long-term goal is to attract well-trained investigators, who hold MD, PhD or MD/PhD degrees, to a career in liver disease research. AASLD currently supports a total of five Liver Scholars.

Objective
These awards are for the purpose of developing the potential of outstanding, young scientists and encouraging research in liver physiology and disease. Therefore, individuals who already are well established in the field are not considered eligible for this award.

American Association for the Study of Liver Diseases
1001 North Fairfax, Suite 400
Alexandria, Virginia 22314
Phone: 703-299-9766
Fax: 703-299-9622
Email: aasld@aasld.org

Hepatologist, Young Investigator, Young Scientist, Physician Researcher
American Association of Anatomists Postdoctoral Fellowship
American Association of Anatomists
All Regions
10/01/2008
$21,000

AAA Postdoctoral Fellowship Program
Application deadline: October 1st

The AAA Postdoctoral Fellowship, established in 2008, offers salary support to AAA members who are postdoctoral fellows working in any aspect of biology relevant to the anatomical sciences. Either the postdoctoral applicant or the host sponsor (or both) must be a permanent resident of the US or Canada, however, fellowships can be used in any country. Applicants must have been AAA members for one year preceding the application deadline and are expected to remain members for the duration of the fellowship. Candidates should be working on a research project encompassing any aspect of biology that is relevant to the anatomical sciences. Approaches can include (but are not limited to) cellular, molecular, genetic or histological techniques, and/or emphasize development, evolution, morphology or human health.

AAA Postdoctoral Fellowship recipients receive:
• A $20,000 Fellowship
• Travel reimbursement (up to $1,000) plus registration fee to present his/her work at the next appropriate AAA Annual Meeting.

American Association of Anatomists
9650 Rockville Pike Bethesda, Maryland 20814-3998
Tel: 301-634-7910 Fax: 301-634-7965 exec@anatomy.org

Biologist, Cell Biologist, Molecular Biologist , Scientist, Anatomist
Marcel Loncin Research Prize
Institute of Food Technologists
All Regions
12/01/2009
$50,000

Marcel Loncin Research Prize
The Marcel Loncin Research Prize, given every other year, was first awarded in 1994. It honors and provides research funding to an IFT member or nonmember scientist or engineer conducting basic chemistry/physics/engineering research applied to food processing and improvement of food quality.

The award is sponsored by the Lomi Foundation Endowment Fund of the Institute of Food Technologists.Foundation.

AWARD: $50,000 paid in two annual installments and a plaque

DEADLINE: December 1, 2009

PURPOSE: The prize, given every other year, was first awarded in 1994. To honor and provide research funding for an IFT-member or nonmember scientist or engineer conducting basic chemistry/physics/engineering research applied to food processing and improvement of food quality. Prize money is to be used by the recipient in directing and carrying out a proposed research project, and to allow a successful scientist to help a young scientist(s) to also become successful.

ELIGIBILITY: The application must be submitted by an individual eligible to carry out the research; i.e., it is not to be a joint research proposal or a laboratory-manager proposal, although cooperative research is encouraged. The applicant may be from academia, industry, or government, and the organization must verify on the application that it will agree to allow the applicant to work on the proposed research.

SPECIAL REQUIREMENTS: The application form must be accompanied by a 5-page grant proposal and a one-page biographical sketch. The proposal should include an introduction with specific objectives, a short critical review of the literature, and a description of the proposed methods. The research proposal must show potential cross-fertilization and cooperation among academia, the food industry, and government organizations where possible. A purely analytical chemistry proposal will not qualify.

The recipient of the prize will be announced during the 2010 IFT Annual Meeting. At the 2011 Annual Meeting, the recipient will make an oral, informal progress report at a breakfast/luncheon meeting attended by the confidential research jury. At the 2011 Annual Meeting, the recipient must (1) review the results of his/her study at a breakfast/luncheon meeting attended by the confidential research jury and (2) make an oral presentation of the results of the study as part of the technical program. The recipient must submit an abstract for oral presentation and must make the presentation in person. If appropriate, a Division may sponsor the recipient as a plenary speaker for one of the technical sessions or symposia.

RESTRICTIONS: The prize money may not be used exclusively and specifically for purchase of new equipment. Also, the prize money cannot be used for salary for the prize recipient but can be used in part for salary of support personnel or graduate students as long as their work is directly related to the research proposal. Only 10% of the prize may be used for travel expenses and then only for travel to the IFT Annual Meeting. The recipient must agree not to charge any overhead expenses against prize money.

Institute of Food Technologists
525 W. Van Buren, Ste. 1000
Chicago, IL 60607
Phone: 312.782.8424
Fax: 312.782.8348
Email: info@ift.org

Novel Approaches to Drug Discovery for Alzheimer's Disease Request For Proposals
Alzheimer's Drug Discovery Foundation
All Regions
10/01/2008
$0
NOVEL APPROACHES TO DRUG DISCOVERY FOR ALZHEIMER’S DISEASE
REQUEST FOR PROPOSALS
Scope of the Program
The objective of this Request for Proposals (RFP) from the biotechnology industry and academia is to catalyze and accelerate the discovery and development of innovative and effective treatments for Alzheimer’s disease. The program will fund high throughput screening of novel targets to identify hits and leads, lead validation and optimization through medicinal chemistry, and pre-clinical in-vitro and in-vivo evaluation, including pharmacology, toxicology, pharmacokinetics, formulation chemistry and the conduct of pre-clinical “proof of concept” studies.
A KEY FUNDING PRIORITY IS THE SUPPORT OF AD DRUG DISCOVERY IN EMERGING BIOTECH COMPANIES
The total number of grants awarded will be dependent upon the numbers, quality and costs of applications received. Proposals covering two years may be submitted, although the second year of funding will be contingent upon progress of the completed work, the investigator’s second-year work-plan, and the numbers and quality of competing proposals. Only one year of funding will be guaranteed. Former recipients of ADDF and ISOA funding are eligible to apply.
Funding Mechanism
If the award recipient is a biotechnology company, ADDF shall provide the grant funding in the form of a convertible note, an equity investment or a recoverable grant based on mutually agreed and negotiated terms.
If the award recipient is an academic institution, then ADDF shall provide funding in the form of an academic grant with terms that provide the Foundation with a return on its investment in the event of commercial success as a result of the research program funded by the Award as negotiated and mutually agreed.
Reporting Requirements
Scientific and financial progress reports are due every six months after the start of the award. A final report of research activities and expenditures is due at the termination of the funding period.
Eligibility Criteria
The proposed research may be conducted at a registered public or private biotechnology company or at any type of not-for-profit academic setting and the Principal Investigator must hold an MD or PhD degree.
Application Guidelines and Selection Criteria
All applications and supporting materials must be received by October 1, 2008. Applications will be reviewed by a Scientific Review Committee (SRC) and a final decision will be made by December 31, 2008.
The following criteria will be used to determine the merit of an application:
• Merit and feasibility of the proposed research and its relevance to drug discovery and development for treatment of Alzheimer’s disease.
• Qualifications of the scientific staff conducting the studies.
• Excellence of the research environment, including the availability of a multidisciplinary research team comprised of neuroscientists, medicinal chemists, pharmaceutical scientists, and the necessary animal models, facilities and equipment required for drug discovery and drug development. Research can be outsourced and consultants employed where appropriate and adequately justified.
• Likelihood that the project will lead to advancement in the treatment of Alzheimer’s disease.
Application Procedures
Application forms are available at www.AlzDiscovery.org.
Medicinal Chemist, Clinical Chemist, Clinical Pharmacist, Laboratory Director, Neurologist, Neuroscientist, Pharmacist, Pharmacy Faculty
Request for Skin Cancer Career Development Awards: SPORE—Skin Cancer
Brigham and Women’s Hospital
All Regions
07/15/2008
$0
Request for Skin Cancer Career Development Awards: SPORE—Skin Cancer
The SPORE in Skin Cancer is seeking one (1) career development project for funding in the sixth year of the grant. SPORE’s are large NCI interdisciplinary program grants which focus on translational research in a specific human disease field (e.g. skin cancer, including melanoma, squamous cell carcinoma, cutaneous lymphoma, etc.). They emphasize the rapid movement of discoveries made in the lab to the clinical setting, and promote laboratory investigations seeking to explain clinical observations.

Specifically, independent investigators with an interest in studying biologic, epidemiologic, preclinical or therapeutic modalities, which are directly or potentially applicable to human skin cancer, are encouraged to apply. All career development projects must have a goal to be translatable in the study of human skin cancer. Awardees will be expected to participate in the activities of the SPORE, including attending research retreats and presenting research accomplishments. The goal of the Career Development Award Program is to attract basic, translational and clinical investigators into skin cancer research, to enrich their foundation of knowledge about human skin cancer, mentor them in their chosen career pathways, and integrate the recipients into the translational mission of the SPORE.

Candidates may be either clinicians or basic scientists with an MD or PhD degree, who are interested in translational research and in pursuing a career as an independent investigator in cutaneous oncology research. We will consider senior level postdoctoral fellows who are moving into faculty status and instructor level junior faculty within three years of completing their training who are interested in pursuing hypothesis driven research. The typical applicant is a junior faculty member with a strong program of research, a secure position in a mentoring environment, and the need for funding as a bridge to independence. Consideration is also given to established investigators interested in shifting their research focus to skin cancer.

Examples of projects, which might be suitable for developmental projects, include:
• New diagnostic tests/techniques for identifying or characterizing skin cancer
• Work with animal models of skin cancer
• Study potential genes and/or proteins important in skin carcinogenesis
• Therapeutic trials

Applications should be no more than 5 pages. Please follow the format outlined below.

• Detailed Budget (not counted in the 5 page limit)
• Introduction and Specific Aim
• Preliminary data
• Experimental design
• References (not counted in 5-page limit)

Application Timelines:

Applications are due July 15, 2008
Funding will begin September 1, 2008

Applications should be sent to:

Brigham and Women’s Hospital
Michelle Gagne
Department of Dermatology
801 Massachusetts Ave. Suite 718
Boston, MA 02118

For additional information please contact Michelle Gagne at 617-582-0080 or mgagne1@partners.org
Physician Researcher, Junior Faculty, Junior Investigator, Junior Researcher, Junior Scientist, Oncologist
Commercialization Grants
Epilepsy Therapy Project
All Regions
08/01/2008
$100,000

Commercialization Grants

Letter of Intent due: AUGUST 1, 2008
If the LOI is accepted, APPLICATION is due: SEPTEMBER 15, 2008

The Epilepsy Therapy Project - Matching Grants Towards the Commercialization of Promising Therapies
The Epilepsy Therapy Project offers 1:1 matching grants of up to $100,000 to academic and commercial entities to support the commercialization of novel approaches to the treatment of epilepsy. These matching funds seek to leverage other resources, and accelerate the pace of therapeutic advance. Proposals will be evaluated by our Scientific Advisory Board together with our Business Advisory Board. We seek to fund discrete steps along the commercial pathway that if successful will enable a project to gain further funding. We welcome a broad span of proposals. Examples of the kind of work we would hope to support include: pre-clinical evaluation and testing of compounds or devices with novel mechanisms of action; and early clinical proof-of-principal trials of compounds or devices. Below are some specific project areas identified by our SAB, which illustrate the scope of our interests:

Directing a promising therapy towards epilepsy as a clinical pathway for regulatory approval. One example of this is work our founders have done with Cognetix, a Utah-based early stage drug development company utilizing conopeptides. While the company's compound had a number of potential therapeutic uses, the company chose to direct the initial clinical focus for its drug towards epilepsy.
Proof-of-principle trials, where a potentially valuable therapy is introduced to selected patients at leading epilepsy centers, under the close watch of leading epileptologists. A case here would be the use of a magnetic stimulation device therapy, which is being carried out in select leading epilepsy centers.
Helping to commercialize promising new epilepsy assays, which offer the ability to identify different targets using different mechanisms of action. An example here would be UCB Pharma's levetiracetam (Keppra), a new drug that failed earlier assays, but showed promise when screened with more recent assays.
Related to the previous example, we are exploring other promising compounds that have failed earlier assays, but may nonetheless offer value if screened against newer, better assays. While we cannot provide the funds necessary to carry a drug through clinical trials, our funds can help reduce risks in the pre-clinical stage, making subsequent clinical development more feasible. Armed with appropriate pre-clinical data, we can then introduce promising compounds to other investment capital sources for further funding and development.
Preference will be given to proposals that already have a commercial partner engaged to assist with development and to proposals that have committed or matched funding from the sponsoring institution, commercial partner or other third party source.

Proposals for research originating from outside the United States are welcome.

Address questions to grants@epilepsytherapyproject.org.

Investigators must submit a Letter of Intent by August 1, 2008.
The deadline for receipt of full Grant proposals is September 15, 2008.
Full proposals will be accepted only from Investigators whose Letter of Intent was approved.

New Therapy Grants Program
Epilepsy Research Foundation
All Regions
08/01/2008
$0
The New Therapy Grants Program seeks to advance the development of specific new therapies including new medicines and therapeutic devices. Consistent with the theme of translational research, all grant proposals must demonstrate a clear path from the lab to the patient.

Letter of Intent due: AUGUST 1, 2008
If the LOI is accepted, APPLICATION is due: SEPTEMBER 15, 2008
Background
The Epilepsy Research Foundation was created through a unique partnership between two leading epilepsy non-profit organizations, the Epilepsy Therapy Project and the Epilepsy Foundation. Additional support is provided by the Milken Family Foundation and Finding a Cure for Epilepsy and Seizures (FACES). The mission of the Epilepsy Research Foundation is to drive the development of new therapies for epilepsy, accelerating the advancement of research from the laboratory to the patient. The Epilepsy Research Foundation provides grants supporting the research and development of new therapies in both academic and commercial settings worldwide.

ERF grant awards are supplemented by support from: Finding a Cure for Epilepsy and Seizures (FACES) and the Milken Family Foundation Translational Research Awards.

New Therapy Grants Program
The New Therapy Grants Program seeks to advance the development of specific new therapies including new medicines and therapeutic devices. Consistent with the theme of translational research, all grant proposals must demonstrate a clear path from the lab to the patient. Other areas of consideration include but are not limited to:

Seed funding for preliminary and targeted work deemed necessary to explore novel therapeutic approaches
Projects which if successful offer a clear path to downstream development
Proposals that support the commercialization of exceptional academic research projects
Research to bring new approaches and therapy to children
Preference will be given to proposals that already have a commercial partner engaged to assist with development and to proposals that have committed or matched funding from the sponsoring institution, commercial partner or other third party source. Proposals for research originating from outside the United States are welcome.

Address questions to grants@epilepsytherapyproject.org.

Investigators must submit a Letter of Intent by August 1, 2008.
The deadline for receipt of full Grant proposals is September 15, 2008.
Neurologist, Neuroscientist, Physician Researcher
Parker B. Francis Fellowship in Pulmonary Research
Francis Family Foundation
All Regions
10/17/2008
$156,000

The Parker B. Francis Fellowship in Pulmonary Research is intended to support the development of outstanding investigators who plan careers in pulmonary research. We seek to help them as they make the transition to independent, self-supporting, faculty members.

Parker B. Francis Fellowship grants are awarded to institutions for the purpose of providing stipends, fringe benefits, and modest travel expenses in support of qualified post-doctoral fellows or newly appointed assistant professors. Award recipients will thereby be enabled to devote the major part of their professional effort to research related to pulmonary disease and lung biology.

Grants are made for three years of support. It is permissible to maintain support for the awardee as he or she moves from fellowship to faculty status. Awards are made to institutions on behalf of the fellows and can be transferred to other institutions only under special circumstances with prior approval from the Director of the Fellowship Program.

Fellows supported by a Parker B. Francis Fellowship must be assured of having at least 75 percent of their time available for research. This means that a total of no more than three months per year may be spent in clinical or other non-research activities.

GENERAL INFORMATION

APPLICANTS
The ideal candidate is one with evidence of strong aptitude in research and who is in transition from post-doctoral trainee to independent investigator. It is essential that there be evidence of accomplishment and proficiency in research. Few applicants who are just beginning research training and have only one or two research publications are funded. Candidates with greater than seven years since the doctoral degree should include reasons for continued training. Candidates may hold any relevant doctoral degree (e.g., M.D., Ph.D., Sc.D., D.V.M., Dr. P.H.). Fellowships are restricted to US, Canadian and Mexican citizens or permanent residents. However, foreign nationals who document their initial steps toward permanent residence in the US, Canada or Mexico will also be considered. Documentation should include a description of steps already taken toward application for long-term residency or citizenship.

MENTORS
Mentorship of the fellow by an established investigator is required. Any established faculty scientist at a university or a not-for-profit research institution may mentor a candidate for fellowship. Mentors at government or corporate laboratories are not eligible. The mentor should be in a position to guarantee that 75 percent of a fellow's time is available for research. The mentor should be committed to fostering the candidate's career advancement and should be the primary scientific advisor. Secondary scientific mentors at the same or a different institution are encouraged but not required. Their roles should be described in the body of the application. Many fellows spend some portion of their fellowship years working with a secondary mentor at another institution.

INSTITUTIONS
There are no restrictions regarding discipline or department. Clinical or basic science departments are suitable; however, it is expected that the proposed research will focus on lung biology or lung disease. Awards are limited to institutions located in the US, Canada and Mexico. Each department may submit only one application annually and is limited to a maximum of two active fellowships at any one time.

NOTES ABOUT OTHER GRANT SUPPORT

Having an NIH K series or similar award at the time of application makes one ineligible for a PBF Fellowship. However, once awarded, a PBF Fellow may accept such a grant, as long as the basic requirements of the PBF Fellowship are met (75 percent of time available for research and PBF funds used only for salary and travel). Most importantly, the area of lung research pursued should remain the same.
Previous individual or institutional NIH or MRC training grants do not make one ineligible, although they must be relinquished if a PBF Fellowship is awarded.
Individuals are ineligible for a PBF Fellowship if they are the principal investigator on an NIH RO1 or similar research grant when applying for a PBF Fellowship. But Fellows in their second or third year may have their own NIH RO1 or similar grant. In fact, obtaining research grants is an appropriate goal for PBF Fellows. Since fellowship funds are restricted to the Fellow's salary and travel, in some cases it may not be possible to utilize the full level of PBF Fellowship support.
Awards will not be given if either the fellow or mentor currently holds funding from the tobacco industry, even if the tobacco monies will not be used to support the PBF sponsored research.
APPROPRIATE TOPICS
A broad array of approaches to lung biology and respiratory medicine, ranging from cell and molecular studies, to those involving epidemiologic and clinical aspects of human subjects are appropriate. We also encourage applications from pulmonary medicine specialists interested in pursuing research in bioethical aspects of pulmonary medicine or critical care. Potential topics include, but are not limited to, the ethics of clinical trials in critical care, end-of-life decisions and resource allocation. The context of all these topics should be pulmonary biology and lung disease. Applicants must meet all the eligibility standards. Mentors and/or applicants considering whether a particular area is appropriate are encouraged to discuss potential projects with the Director of the PBF Fellowship Program in Seattle, Washington (trmartin@u.washington.edu).

MAILING ADDRESS

Thomas R. Martin, M.D.
Director
Parker B. Francis Fellowship Program
Pulmonary Research Laboratories
VA Puget Sound Health Care System
1660 S. Columbian Way, 151L
Seattle, WA 98108

DEADLINE

Applications must be received no later than Friday, October 17, 2008.

Junior Faculty, Junior Investigator, Junior Researcher, Junior Scientist, Pulmonologist , Young Investigator, Young Scientist, Cell Biologist, Molecular Biologist , Epidemiologogist
Talecris New Trials Support (Talents) Program
Talecris Biotherapeutics
All Regions
08/01/2008
$300,000

The Talents Program

Letters of Intent (LOI) for the next round of awards are due by August 1, 2008. Disbursements of grants will begin early in January 2009.

The Talents Program has three key aims:

Further the understanding of the efficacy and mechanisms of action of IGIV in current clinical indications
Explore new clinical uses of IGIV
Support the intellectual endeavors of the IGIV research community.
Grants are awarded on an annual basis and are usually for either a 1- or 2-year period. Grants can include support for salary, overheads and direct costs. Product may also be provided if requested.

The program awards up to $1 million a year. Individual grants can be up to $150,000 per research project per annum, excluding product costs. The maximum funding available per research project is therefore $300,000 awarded over a 2-year period.

The funding cycle takes place on an annual basis. Letters of Intent are reviewed in August, funding is determined in October, and funding begins in January of the following year.

How to Apply
The Application Process
Applications are made in two steps. The first step requires the completion of a Letter of Intent, of which there are two versions: one for basic science projects and one for clinical research projects.

Letters of Intent will be reviewed by The Talents Evaluation Committee, which includes experts in neurology, immunology, hematology, and other disciplines as needed, as well as Talecris scientists.

Investigators who submit Letters of Intent that are approved by the Talents Evaluation Committee will be asked to complete a full application form, which will be emailed to those applicants.

As with the Letters of Intent, the completed applications will be reviewed by members of the Talents Evaluation Committee; and the committee will determine which proposals will be funded.

Each application will be reviewed based on the following set of criteria:

Scientific merit
Qualifications of applicant
Quality of environment
Alignment with program goals.

All proposals that meet minimum criteria in the above categories will be ranked and funded until the allotted funds are exhausted.

Who Should Apply?
Applications are welcome from individuals with an MD, PhD, DO or PharmD who are affiliated with a facility that utilizes IGIV in a basic or clinical science research setting or to treat patients. Such facilities may include, but are not limited to, universities, hospitals, clinics, blood centers, and laboratories.

For-profit organizations are not eligible for funding under the Talents Program, e.g. pharmaceutical companies, homecare companies, health maintenance organizations. If you require additional information, please contact the Program Administrator at: talents@porterhouse.biz.

Clinical Pharmacist, Immunologist, Neurologist, Physician Researcher, Hematologist, Scientist

23456789101116next